A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
Learn more: Researchers’ discovery could lead to improved therapies for Duchenne muscular dystrophy
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Duchenne muscular dystrophy
- These 15 One-of-a-Kind Watches Won’t Appear at the OnlyWatch Auction. We Asked the Brands Why.on April 26, 2024 at 9:00 am
We asked 15 brands why their unique timepieces for OnlyWatch will not appear at the rescheduled auction in Geneva next month, and what the fate of those watches might be.
- Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Findson April 25, 2024 at 2:03 pm
The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
- DeWine: Ohio first state in the nation to screen newborn babies for Duchenne Muscular Dystrophyon April 24, 2024 at 9:00 pm
Ohio Gov. Mike DeWine on Monday announced that Ohio will become the first state in the nation to begin screening all newborn babies for Duchenne Muscular Dystrophy. The provision was included in HR 33 ...
- Gov. DeWine announces Ohio will be first state to screen newborns for DMDon April 24, 2024 at 7:23 am
Gov. Mike DeWine announced Tuesday that the state of Ohio will become the first in the United States to screen all newborn babies for Duchenne muscular dystrophy.
- Glucocorticoid use can aid breathing ability in Duchenne adults: Studyon April 23, 2024 at 8:28 am
Glucocorticoid use was seen to help maintain breathing ability and arm function in adults in the late stages of Duchenne muscular dystrophy.
- Duchenne UK and Parent Project Muscular Dystrophy Award $500,000 to Evaluate Safety and Tolerability of Muscle Progenitor Cells in Phase 1 Trialon April 23, 2024 at 7:01 am
Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization, and the UK charity Duchenne UK, two leading organizations dedicated to ending Duchenne muscular dystrophy (Duchenne), are excited ...
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 6:01 am
Finally, when we were approved for evaluation, we received a devastating diagnosis: Duchenne muscular dystrophy. Duchenne is a rare, progressive disorder in which muscle cells are in a constant ...
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 5:01 am
Opinion: Newborn testing can give families a head start on giving a child with the degenerative muscular disease a shot at the best outcome in life.
- An FDA pathway can accelerate innovation for Duchenne muscular dystrophyon April 22, 2024 at 1:31 am
Few treatments are available for people with Duchenne muscular dystrophy. The FDA's accelerated approval program can help change that.
via Bing News